Inhibrx Biosciences, Inc. (INBX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenue | 1,300 | - | 100 | |
| Research and development | 22,267 | 38,893 | 67,632 | |
| General and administrative | 6,422 | 7,904 | 93,366 | |
| Total operating expenses | 28,689 | 46,797 | 160,998 | |
| Loss from operations | -27,389 | -46,797 | -160,898 | |
| Other income (expense), net | -246 | 41 | 33 | |
| Gain related to transaction with acquirer | - | - | 2,021,498 | |
| Interest expense | 3,141 | - | 5,361 | |
| Interest income | 2,124 | 2,892 | 2,741 | |
| Total other income (expense) | -1,263 | 2,933 | 2,018,911 | |
| Income (loss) before income tax expense | -28,652 | -43,864 | 1,858,013 | |
| Provision for income taxes | 2 | - | 2 | |
| Net income (loss) | -28,654 | -43,864 | 1,858,011 | |
| Basic (in dollars per share) | -1.85 | -2.84 | 127.1 | |
| Basic (in shares) | 15,468,000 | 15,468,000 | 14,619,000 | |
| Diluted (in dollars per share) | -1.85 | -2.84 | 125.48 | |
| Diluted (in shares) | 15,468,000 | 15,468,000 | 14,807,000 | |